Advertisement

Some historical aspects of drug treatment for obesity

  • George A. Bray
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

Janus was the Roman god with two faces — one face smiling, one scowling [2, 3]. He is frequently seen as the symbol for theater — tragedy and comedy being his two faces. Amphetamine, the first drug with a clinical trial showing effectiveness in the battle of the bulge, also has two faces. One face was suppression of appetite, the other face was addiction. It was this latter frowning face that has cast a cloud of doubt and concern over pharmacological agents developed to help in the battle of the bulge. This is the story.

Keywords

Thyroid Hormone Thyroid Gland Valvular Heart Disease Reduce Food Intake Historical Aspect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Osier W (1891) Recent Advances in Medicine. Science 17: 170–171CrossRefGoogle Scholar
  2. 2.
    Temkin O (1977) The double face of Janus. In: The double face of Janus and other essays in the history of medicine. Johns Hopkins University Press, Baltimore, 3–37Google Scholar
  3. 3.
    Koestler A (1978) Janus. A summing up. Random House, New YorkGoogle Scholar
  4. 4.
    Lesses MF, Myerson A (1938) Human autonomic pharmacology XVI: benzedrine sulfate as an aid in the treatment of obesity. N Engl J Med 218: 119–124CrossRefGoogle Scholar
  5. 5.
    Putnam JJ (1893) Cases of myxoedema and acromegalia treated with benefit by sheep’s thyroids: recent observations respecting the pathology of the cachexias following disease of the thyroid; clinical relationships of Grave’s disease and acromegalia. Am J Med Sci 106: 125–148Google Scholar
  6. 6.
    Gull WW (1873–1874) On a cretinoid state supervening in adult life in women. Trans Clin Soc Lond 7: 180–185Google Scholar
  7. 7.
    Kendall EC (1915) The isolation in crystalline form of the compound containing iodine, which occurs in the thyroid; its chemical nature and physiologic activity. JAMA 64: 2042–2043Google Scholar
  8. 8.
    Harington CR (1926) Chemistry of thyroxine I. Biochem J 20: 293–313PubMedGoogle Scholar
  9. 9.
    Gross J, Pitt-Rivers RV (1953) 3:5:3’-Triiodothyronine. I. Isolation from thyroid gland and synthesis. Biochem J 53: 645–650PubMedGoogle Scholar
  10. 10.
    Atwater WO, Rosa EB (1899) Description of a new respiration calorimeter and experiments on the conservation of energy in the human body. Bulletin of the US Department of Agriculture Office of Experimental Stations, #63Google Scholar
  11. 11.
    DuBois EF (1924) Basal metabolism in health and disease. Lea and Febiger, PhiladelphiaGoogle Scholar
  12. 12.
    Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C (1986) Determinants of 24-hour energy expenditure in man: methods and results using a respiratory chamber. J Clin Invest 78: 1568–1578PubMedCrossRefGoogle Scholar
  13. 13.
    Bray GA, Melvin KEW, Chopra IJ (1973) Effect of triiodothyronine on some metabolic responses of obese patients. Am J Clin Nutr 26: 715–721PubMedGoogle Scholar
  14. 14.
    Edwards DAW, Sawyer GIM (1950) The comparative values of dextroamphetamine sulphate, dried thyroid gland and a placebo in the treatment of obesity. Clin Sci 9(2): 115–126Google Scholar
  15. 15.
    Gelvin EP, McGavack TH (1949) Dexedrine and weight reduction. NY State J Med 49: 279–282Google Scholar
  16. 16.
    Lyon DM, Dunlop DM (1932) The treatment of obesity: a comparison of the effects of diet and of thyroid extract. Quart J Med 1: 331–352Google Scholar
  17. 17.
    Ehrlich P, Hata S (1910) Die experimentelle Chemotherapie der Spirillosen. Julius Springer, BerlinGoogle Scholar
  18. 18.
    Bray GA (1976) The obese patient major problems in internal medicine. W.B. Saunders Company, PhiladelphiaGoogle Scholar
  19. 19.
    Simkins S (1937) Dinitrophenol and desiccated thyroid in the treatment of obesity: a comprehensive clinical and laboratory study. JAMA 108: 2110–2193Google Scholar
  20. 20.
    Leake CD (1958) The amphetamines. Their actions and uses. Charles C. Thomas, Springfield, ILGoogle Scholar
  21. 21.
    Harris SC, Ivy AC, Searle LM (1947) The mechanism of amphetamine-induced loss of weight. A correlation of the theory of hunger and appetite. JAMA 134: 1468–1474Google Scholar
  22. 22.
    Barger G, Dale HH (1910) Chemical structure and sympathomimetic action of amines. J Physiol 41: 19–59PubMedGoogle Scholar
  23. 23.
    Prinzmetal M, Bloomberg W (1935) The use of benzedrine for the treatment of narcolepsy. JAMA 105: 2051–2053Google Scholar
  24. 24.
    Myerson A (1936) Effect of benzedrine sulfate on mood and fatigue in normal and in neurotic persons. Arch Neurol Psych 36: 816–822Google Scholar
  25. 25.
    Nathanson MH (1937) The central action of beta-aminopropylbenzene (Benzedrine). JAMA 108: 528–531Google Scholar
  26. 26.
    Davidoff E, Reifenstein EC Jr (1937) The stimulating action of benzedrine sulfate: a comparative study of the responses of normal persons and of depressed patients. JAMA 108: 1770–1776Google Scholar
  27. 27.
    Ulrich H (1937) Narcolepsy and its treatment with benzedrine sulfate. N EngI J Med 217(18): 696–701CrossRefGoogle Scholar
  28. 28.
    Leibowitz SF, Rossakis C (1978) Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol. Eur Pharm 53: 69–81CrossRefGoogle Scholar
  29. 29.
    Roberts RM (1989) Serendipity. Accidental discoveries in science. John Wiley and Sons, New YorkGoogle Scholar
  30. 30.
    Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine [see comments] N Engl J Med 337: 581–588PubMedCrossRefGoogle Scholar
  31. 31.
    Weintraub M (1992) Long-term weight control, the National Heart, Lung and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 51(5): 581–585PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • George A. Bray
    • 1
  1. 1.Pennington Biomedical Research CenterBaton RougeUSA

Personalised recommendations